CORONA Remedies Share Price Prediction 2027: Scenario Targets, Valuation and Technical Outlook

The CORONA Remedies share price forecast comes down to earnings growth and the multiple investors pay for it, and the reported numbers give a measured answer. The stock trades at Rs 2,009.30 on NSE as of 9 October 2026, 12.3% below its 52-week high of Rs 2,292.40, after the company reported net profit of Rs 185.12 crore for FY26.

This CORONA Remedies stock forecast 2027 builds conservative, base and bull scenarios from exchange-reported financials, shareholding data and daily price indicators, with every assumption shown.

Click Here – Get Free Investment Predictions

CORONA Remedies Share Price Today and Key Data

The CORONA Remedies share price today is Rs 2,009.30 on NSE, up 0.79% on the day. The market capitalisation stands at Rs 12,156 crore. Over the past year the price has risen 39.7% from Rs 1,438.40. Every CORONA Remedies stock forecast figure below starts from this price.

Metric	Value
Company	CORONA Remedies (CORONA)
Current Price	Rs 2,009.30
52-Week High	Rs 2,292.40 (15 September 2026)
52-Week Low	Rs 1,336.60 (23 December 2025)
Market Cap	Rs 12,156 crore
PE Ratio	61.08
Industry PE	37.59
PB Ratio	16.28
EPS (TTM)	Rs 32.54
Return on Equity	24.79%
Debt to Equity	0.22
Dividend Yield	0.50%
Book Value per Share	Rs 122.12

What Is the CORONA Remedies Share Price Prediction for 2027?

The CORONA Remedies share price prediction for 2027 is a conservative case of Rs 2,311, a base case of Rs 2,411 and a bull case of Rs 2,512. Against Rs 2,009.30, these imply 15.0% upside, 20.0% upside and 25.0% upside. They are model scenarios built from reported EPS growth, not broker targets.

Scenario	EPS Growth Basis	EPS Estimate	PE Multiple	Implied Value	Upside vs Current Price
Conservative Case	Lower of FY26 growth (23.9%) and 3-year CAGR (27.6%) (capped at 15%)	Rs 37.42 (+15.0%)	Unchanged from today (price to EPS ratio kept constant)	Rs 2,311	+15.0%
Base Case	Average of the two (capped at 20%)	Rs 39.05 (+20.0%)	Unchanged from today (price to EPS ratio kept constant)	Rs 2,411	+20.0%
Bull Case	Higher of the two (capped at 25%)	Rs 40.67 (+25.0%)	Unchanged from today (price to EPS ratio kept constant)	Rs 2,512	+25.0%

Each target takes today's price of Rs 2,009.30 and scales it by the EPS growth assumed for that case, which is the same as holding the PE multiple constant. The conservative case uses the lower of the FY26 EPS growth and the 3-year EPS CAGR, the base case uses their average and the bull case uses the higher figure. Together they form the CORONA Remedies target price range for the FY27 outlook over the next 12 months, and the range is not a point estimate.

CORONA Remedies Share Price Forecast: What Has to Go Right by 2027

Each CORONA Remedies target price below depends on a specific EPS outcome, and the text states that outcome next to the number.

Conservative Case for the CORONA Remedies Share Price Target: Rs 2,311

Reaching Rs 2,311 needs EPS to rise 15.0% to Rs 37.42 while the stock keeps its current PE multiple. That follows the slower 3-year EPS CAGR of 27.6%.

Base Case for the CORONA Remedies Share Price Target: Rs 2,411

Reaching Rs 2,411 needs EPS to rise 20.0% to Rs 39.05, the average of the FY26 growth rate and the 3-year CAGR. Net profit growth of 30.1% in Q1 FY27 is at or above that pace, which supports the target.

Bull Case for the CORONA Remedies Share Price Target: Rs 2,512

Reaching Rs 2,512 needs EPS to rise 25.0% to Rs 40.67 with the PE multiple held at today's level. That is above the 52-week high of Rs 2,292.40, so it would need a fresh breakout. A daily close above the nearest resistance level of Rs 2,109.09 (50-day SMA) would be the first technical confirmation.

CORONA Remedies Financial Performance: Revenue, Profit and Margins

CORONA Remedies earned net profit of Rs 185.12 crore on revenue of Rs 1,413.83 crore in FY26, with profit up 23.9% and revenue up 17.6% compared with FY25. Diluted EPS was Rs 30.27 against Rs 24.43 a year earlier, and that earnings base anchors the CORONA Remedies share price forecast.

Year	Revenue (Rs Cr)	Net Profit (Rs Cr)	EPS (Rs)	Operating Margin	Net Margin
FY23	891.10	84.93	14.57	15.30%	9.53%
FY24	1,020.93	90.50	14.80	15.89%	8.86%
FY25	1,202.35	149.43	24.43	20.59%	12.43%
FY26	1,413.83	185.12	30.27	20.33%	13.09%

In the latest reported quarter, Q1 FY27 (quarter ended June 2026), revenue was Rs 425.58 crore against Rs 348.56 crore a year earlier (+22.1%), and the bottom line was a net profit of Rs 60.11 crore against a net profit of Rs 46.20 crore (+30.1%). Operating margin was 22.79% versus 20.66% in the year-ago quarter. Cash flow from operations was Rs 229.48 crore in FY26 against Rs 190.49 crore in FY25. Together these figures set the earnings base for the CORONA Remedies share price prediction.

Check the Univest Screener for live CORONA Remedies fundamentals

Is CORONA Remedies Overvalued or Undervalued Right Now?

CORONA Remedies trades at a PE of 61.08 against an industry PE of 37.59, which places the stock at a 62.5% premium to the industry average. The price-to-book ratio is 16.28 on a book value of Rs 122.12 per share. Return on equity of 24.79% means the company earns Rs 24.79 of profit for every Rs 100 of shareholder equity.

Debt to equity is 0.22, so borrowings equal about 22% of shareholder equity. The company declared a dividend of Rs 10.00 per share for FY26, a yield of 0.50% at the current price. This valuation context frames the CORONA Remedies stock price prediction for 2027 without relying on any outside forecast.

CORONA Remedies Stock Analysis: Technical Outlook

CORONA Remedies stock trades below its 50-day SMA of Rs 2,109.09 and above its 200-day EMA of Rs 1,846.68, and the combined daily indicators read bearish. The 52-week high of Rs 2,292.40 was set on 15 September 2026, while the 52-week low of Rs 1,336.60 came on 23 December 2025.

Indicator	Reading	Signal
RSI (14)	23.51	Oversold
MACD (12,26,9)	-28.74 vs signal -12.93	Bearish
ADX (14)	35.61	Established trend
Supertrend (10,3)	Price below Rs 2,176.47	Bearish
50-day SMA	Rs 2,109.09	Price below
200-day EMA	Rs 1,846.68	Price above

The nearest support level sits at Rs 1,846.68 (200-day EMA) and Rs 1,336.60 (52-week low). The nearest resistance level sits at Rs 2,109.09 (50-day SMA) and Rs 2,176.47 (Supertrend). A sustained move above the nearest resistance would support the CORONA Remedies share price prediction 2027 base case, and this CORONA Remedies stock analysis uses daily candles only. Chart signals add context to the CORONA Remedies share price target without changing the earnings maths.

CORONA Remedies Shareholding Pattern

Promoters hold 69.00% of CORONA Remedies as of Sep 2026, down from 72.50% in Apr 2025 across the last 5 quarters. FII holding is 4.21% (up from 0.00% in Apr 2025) and DII holding is 16.45% (up from 0.00% in Apr 2025), which puts combined institutional holding at 20.66%. Public shareholders own 10.34%. Shareholding data is one input for any CORONA Remedies stock forecast. Ownership is a useful cross-check on any CORONA Remedies share price prediction.

Key Risks to the CORONA Remedies Share Price Target for 2027

Earnings and Margin Risk

Operating margin has ranged from 15.30% to 20.59% between FY23 and FY26, so a slip toward the lower end would trim the EPS estimate behind the CORONA Remedies stock forecast. Revenue was up 17.6% in FY26, and slower revenue growth would weigh on the profit path.

Valuation Risk

The PE of 61.08 is 62.5% above the industry PE of 37.59. Every target here holds the multiple constant, so a narrowing of that premium would leave returns below these targets even if earnings grow as assumed.

Size and Liquidity Risk

Market capitalisation stands at Rs 12,156 crore. Investors should check daily traded volumes and order book depth on NSE before sizing a position, because price moves can be sharper when volumes thin out. Liquidity is a practical constraint on any CORONA Remedies stock price target.

Balance Sheet Risk

Debt to equity of 0.22 means borrowings stand at about 22% of shareholder equity. A rise in borrowing costs or a jump in debt would weigh on profit and on the multiple behind the CORONA Remedies share price forecast.

Technical Risk

The daily indicators read bearish, so the targets above may need a technical turn before the price follows earnings. A daily close below Rs 1,846.68 (200-day EMA) would weaken the setup further.

Conclusion

This CORONA Remedies stock analysis puts the share price target range for 2027 at Rs 2,311 to Rs 2,512, with a base case of Rs 2,411 against Rs 2,009.30 today. The inputs are a PE of 61.08 that sits at a 62.5% premium to the industry average, EPS growth of 23.9% in FY26 and a daily technical setup that reads bearish. The next quarterly result will show which scenario is gaining ground. This analysis is educational, so consult a SEBI-registered advisor before acting on it.

Download the Univest iOS App or Univest Android App to track CORONA Remedies live price and get daily stock recommendations.

Frequently Asked Questions on CORONA Remedies Share Price Prediction 2027

What is the CORONA Remedies share price target for 2027?

Ans. The CORONA Remedies share price forecast for 2027 has a conservative case of Rs 2,311, a base case of Rs 2,411 and a bull case of Rs 2,512. These are model scenarios based on reported EPS growth, and they are not guaranteed outcomes.

What is the CORONA Remedies share price today?

Ans. CORONA Remedies trades at Rs 2,009.30 on NSE as of 9 October 2026, up 0.79% on the day. The 52-week range is Rs 1,336.60 to Rs 2,292.40.

Is CORONA Remedies a good stock to buy for 2027?

Ans. The data points in different directions: the PE of 61.08 is at a 62.5% premium to the industry average, EPS grew 23.9% in FY26 and the daily technical setup reads bearish. This article does not constitute investment advice, so consult a SEBI-registered advisor before deciding.

Can CORONA Remedies stock reach Rs 2,512 in 2027?

Ans. Reaching Rs 2,512 needs EPS to rise 25.0% from Rs 32.54 with the PE multiple held at today's level, plus a daily close above Rs 2,109.09 (50-day SMA). This is a scenario, not a guarantee.

What are the support and resistance levels for CORONA Remedies?

Ans. The nearest support levels are Rs 1,846.68 (200-day EMA) and Rs 1,336.60 (52-week low), and the nearest resistance levels are Rs 2,109.09 (50-day SMA) and Rs 2,176.47 (Supertrend).

What are the main risks for CORONA Remedies stock in 2027?

Ans. The main risks to the CORONA Remedies share price forecast are a fall in operating margin from the 15.30% to 20.59% range seen since FY23, slower revenue growth after FY26 revenue was up 17.6%, and thin trading volumes. Debt to equity of 0.22 adds balance sheet sensitivity.

How is the CORONA Remedies target price for 2027 calculated?

Ans. Each target scales the current price by assumed EPS growth at a constant PE multiple. The conservative case uses 15.0% growth, the base case 20.0% and the bull case 25.0%, all drawn from the company's reported FY26 and 3-year EPS growth.